Baxter's vaccines, soon to be Pfizer's, help it exceed Q3 guidance; Pfenex and PATH partner up;

> Baxter's ($BAX) marketed vaccines--on their way to Pfizer ($PFE) thanks to a July deal--chipped in $21 million, or $0.04 per diluted share, in net income for Q3. Release

> Pfenex ($PFNX) and PATH have partnered up to enhance vaccine production; the two are working on an initial pilot project for two vaccine components. More

> Vaxart's tablet vaccine for H1N1 influenza generated protective immunity equivalent to an injectable in a Phase I clinical trial. Release

> The International Medica Foundation has licensed to BravoVax a rotavirus vaccine for newborns. More

> Unexpected delays from multiple manufacturers are causing postponements of flu shipments to some healthcare providers, according to distributor FFF. Release

> France's Imaxio has inked an option for a license agreement with the German Center for Cancer Research to evaluate the former's pro-immunogenic technology with a candidate vaccine targeting HPV. More

And Finally... The Vaccine & Gene Therapy Institute of Florida (VGTI Florida) has partnered with Sweden's Karolinska Institutet to fight diseases associated with aging. More (sub. req.)

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

As a new coronavirus spreads, vaccine researchers have started work on candidates against the virus—and one could enter the clinic in a few months.

Merck's HPV vaccine Gardasil is delivering blockbuster sales as demand surges. But high demand has caused somewhat of a supply constraint.